Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
The DOI matches its Crossref record.
Abstract
OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although 60% of persons who achieved remission in the STAR * D trial with level 1 treatment did so after week 6 of treatment”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“The adequate duration of an antidepres sant trial is generally considered to be 4- 6 weeks at optimal dosing”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“the partial responses at 2 weeks have, nonetheless, been shown to be strongly correlated with subsequent remission [19,51].”
Citations
Cited by
Items 101–200 of 341
Vermeiden, M., Kamperman, A. M., Vulink, M. E., van den Broek, W. W., & Birkenhäger, T. K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3765-1 · Cited by 26
Recommendations for Screening for Depression in Adults
Thase, M. E. (2016) · JAMA · doi:10.1001/jama.2015.18406 · Cited by 29
Self-citationXiao, H., Yuan, M., Li, H., Li, S., Du, Y., Wang, M., Zhu, H., Zhang, W., Qiu, C., & Huang, X. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.013 · Cited by 28
Rentzsch, J., Adli, M., Wiethoff, K., de Castro, A. G.-C., & Gallinat, J. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0424-1 · Cited by 29
“[4] showed that a lack of”
Leuchter, M. K., Citrenbaum, C., Wilson, A. C., Tibbe, T. D., JACKSON, N. J., Krantz, D. E., Wilke, S. A., Corlier, J., Strouse, T. B., Hoftman, G. D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115608 · Cited by 25
Kolouri, S., Firoozabadi, A., Salehi, A., Zarshenas, M. M., Dastgheib, S. A., Heydari, M., & Rezaeizadeh, H. (2016) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2016.03.016 · Cited by 34
Early improvement with lithium in classic mania and its association with later response
Machado‐Vieira, R., Luckenbaugh, D. A., Soeiro‐de‐Souza, M. G., Marca, G., Henter, I. D., Busnello, J. V., Gattaz, W. F., & Zarate, C. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.039 · Cited by 25
Haji, E. O., Tadić, A., Wagner, S., Dragivevic, A., Müller, M., Boland, K., Rao, M., Fric, M., Laux, G., & Hiemke, C. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1354370 · Cited by 28
Xu, Y., Wei, H., Zhu, Y., Zhu, Y., Zhang, N., Qin, J., Zhu, X., Yu, M., & Li, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.008 · Cited by 25
Clinical differences between early and late remission in depressive patients
Roca, M., García-Toro, M., García‐Campayo, J., Vives, M., Armengol, S., García-García, M., Asensio, D., & Gili, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.051 · Cited by 30
“Early improvement predicted stable response and stable remission with high sensitivity in a meta-analysis of 41 studies including 6500 patients (Szegedi et al., 2009).”
BackgroundKato, M., Serretti, A., Nonen, S., Takekita, Y., Wakeno, M., Azuma, J., & Kinoshita, T. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.6 · Cited by 25
Kato, M., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., Nishida, K., Nonen, S., Higasa, K., & Kinoshita, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073873 · Cited by 23
“Although the aforementioned two studies assessed the correlation with 8-week remission, whereas we focused on early responses, the partial responses at 2 weeks have, nonetheless, been shown to be strongly correlated with subsequent remission [19,51].”
BackgroundResultSoares, C. N., Fayyad, R. S., & Guico‐Pabia, C. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000049 · Cited by 24
Samochowiec, J., Dudek, D., Kucharska–Mazur, J., Murawiec, S., Rymaszewska, J., Cubała, W. J., Heitzman, J., Szulc, A., Bała, M. M., & Gałecki, P. (2021) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/132496 · Cited by 39
“The cutoff for the assessment of early threshold response is the 20% reduction of depression severity from the baseline [45].”
BackgroundEarly Improvement Predicts Clinical Outcomes Similarly in 10 Hz rTMS and iTBS Therapy for Depression
Spitz, N. A., Pace, B., Eyck, P. T., & Trapp, N. T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863225 · Cited by 26
Romera, I., Pérez, V., Menchón, J. M., Schacht, A., Papen, R., Neuhauser, D., Abbar, M., Picard, H., & Gilaberte, I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.024 · Cited by 24
Gudayol‐Ferré, E., Guàrdia‐Olmos, J., Peró, M., Herrera‐Guzmán, I., Camarena, B., Cortés‐Penagos, C., Herrera‐Abarca, J. E., & Martínez‐Medina, P. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.024 · Cited by 24
“It is true that several papers suggest that an early improvement of MDD is linked to a more stable later outcome (Stassen et al., 2007; Henkel et al., 2009; Szegedi et al., 2009; Tadić et al., 2010; Kim et al., 2011).”
BackgroundResultInfluentialAngstman, K. B., Pietruszewski, P. B., Rasmussen, N. H., Wilkinson, J. M., & Katzelnick, D. J. (2012) · Europe PMC (PubMed Central) · Cited by 24
Schaffer, A., Kreindler, D., Reis, C., & Levitt, A. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829e8359 · Cited by 22
“The selection of a greater than or equal to 20% decline is in keeping with definition of early changes used in the MDD and Bipolar depression literature.(30,47) Self-report response was defined as a reduction of greater than or equal to 50% in QIDS-SR total score from baseline to Schaffer et al Journal of Clinical Psy…”
MethodSoares, C. N., Endicott, J., Boucher, M., Fayyad, R. S., & Guico-Pabia, C. J. (2014) · CNS Spectrums · doi:10.1017/s1092852914000066 · Cited by 22
Zhao, Y., Dahmani, L., Li, M., Hu, Y., Ren, J., Lui, S., Wang, D., Kuang, W., Gong, Q., & Liu, H. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.12.010 · Cited by 28
Farahani, R. H., Ajam, A., & Naeini, A. R. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08172-5 · Cited by 23
Taylor, R., Marwood, L., Greer, B., Strawbridge, R., & Cleare, A. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119872194 · Cited by 25
Lipsitz, O., McIntyre, R., Rodrigues, N. B., Kaster, T., Cha, D., Brietzke, E., Gill, H., Nasri, F., Lin, K.-G., Subramaniapillai, M., et al. (2020) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 22
Rizvi, S. J., Geraci, J., Ravindran, A. V., & Kennedy, S. H. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000211 · Cited by 25
Johnson, C. F. A., Maxwell, M., Williams, B., Dougall, N. J., & MacGillivray, S. A. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000017 · Cited by 35
“101 102 One meta-analysis identified in this review indicated that 50% of response effect was achieved by four weeks of treatment.”
BackgroundXiao, L., Zhu, X., Gillespie, A. L., Feng, Y., Zhou, J., Chen, X., Gao, Y., Wang, X., Ma, X., Gao, C., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291719004069 · Cited by 21
“…of MDD patients did not show early improvement in response to antidepressant treatment and 43% did not show early improvement in response to SSRIs specifically (Wagner et al., 2017); an earlier meta-analysis similarly reports that 37% did not show early improvement to SSRIs (Szegedi et al., 2009).”
BackgroundMethodResultInfluentialAlbert, U., Lamba, P., & Stahl, S. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000304 · Cited by 19
The network analysis of depressive symptoms before and after two weeks of antidepressant treatment
Zhou, J. L., Liu, S., Mayes, T. L., Feng, Y., Fang, M., Xiao, L., & Wang, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.059 · Cited by 25
Pharmacological Treatment of Unipolar Depression
Anderson, I. M. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_208 · Cited by 21
Furey, M. L., Drevets, W. C., Szczepanik, J., Khanna, A., Nugent, A., & Zarate, C. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv028 · Cited by 21
“Several metaanalyses have reported that clinical status observed at 2 weeks into conventional antidepressant treatment is predictive of subsequent clinical response (Szegedi et al., 2009; Gorwood et al., 2013), allowing for clinical management decisions to be made earlier in the course of treatment.”
BackgroundMa, H., Zhang, D., Wang, Y., Ding, Y., Yang, J., & Li, K. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04966-8 · Cited by 19
“To clarify the earliest time point when improvement occurred, a meta-analysis and an observational study both stated that the response to ADM could occur as early as 2 weeks after initial ADM [10, 11].”
BackgroundFunatsuki, T., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., Nonen, S., Higasa, K., Kinoshita, T., & Kato, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512199 · Cited by 25
Isacsson, N. H., Abdesslem, F. B., Forsell, E., Boman, M., & Kaldo, V. (2024) · Communications Medicine · doi:10.1038/s43856-024-00626-4 · Cited by 20
“However, it is well established that early symptom change during treatment isassociatedwith the symptomatic treatment outcome 12,13 and including predictors from the fi rst weeks of treatment, as in Routine Outcome Monitoring 14 and Adaptive Treatment Strategies, increases the accuracy of…”
Early changes in depression predict outcomes of inpatient adolescent anorexia nervosa
Kahn, M., Klomek, A. B., Hadas, A., Snir, A., & Fennig, S. (2019) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-019-00686-9 · Cited by 23
Bareš, M., Novák, T., Brunovský, M., Kopeček, M., & Höschl, C. (2016) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000574 · Cited by 20
Hart, X. M., Gründer, G., Unterecker, S., Schoretsanitis, G., Hiemke, C., Adamovic, I., Amann, F., Baumann, P., Bergemann, N., Brandt, C., et al. (2026) · Pharmacopsychiatry · doi:10.1055/a-2860-7861 · Cited by 23
Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?
Stuchtey, F. C., Block, A., Osei, F., & Wippert, P. (2022) · Healthcare · doi:10.3390/healthcare10020333 · Cited by 25
“Interestingly, a meta-analysis revealed that an early improvement of depressive symptoms with antidepressant medication predicted a stable response and remission in MDD therapy [26].”
BackgroundZhang, A., Wang, X., Li, J., Jing, L., Hu, X., Hejun, L., Yang, C., Zhang, K., & Sun, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.831278 · Cited by 18
Sackeïm, H. A., Aaronson, S. T., Carpenter, L. L., Hutton, T. M., Pages, K. P., Lucas, L., & Chen, B. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.02.019 · Cited by 21
“…that there is inconsistency in the literature in the use of this terminology with some studies following the definitions in Table 2 [2,13] and other studies defining correct prediction of nonresponse as a True Negative detection, with NPV assessing the accuracy of such prediction [21,39 – 41].”
BackgroundMethodResultInfluentialEarly identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9)
Fowler, J. C., Patriquin, M. A., Madan, A., Allen, J. G., Frueh, B. C., & Oldham, J. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.018 · Cited by 21
Jain, R., Chen, D., Edwards, J., & Mathews, M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.855188 · Cited by 21
Yoshida, K., Roberts, R., Suzuki, T., Lebowitz, B. D., Reeves, S., Howard, R. J., Abe, T., Mimura, M., & Uchida, H. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.01.016 · Cited by 24
Bhat, S., Kroehl, M., Trinkley, K. E., Chow, Z., Heath, L. J., Billups, S. J., & Loeb, D. F. (2018) · Population Health Management · doi:10.1089/pop.2017.0144 · Cited by 25
Harris, J. K., Hassel, S., Davis, A. D., Zamyadi, M., Arnott, S. R., Milev, R. V., Lam, R. W. M., Frey, B. N., Hall, G. B., Müller, D. J., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103120 · Cited by 22
“Early symptom response to antidepressant medication has been well established to be one of the strongest predictors of treatment response to date (Jakubovski and Bloch, 2014; Szegedi et al., 2009).”
BackgroundReview: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
Lam, R. W. M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372979 · Cited by 20
Wagner, S., Helmreich, I., Wollschläger, D., Meyer, K., Kaaden, S., Reiff, J., Roll, S. C., Braus, D. F., Tüscher, O., Müller‐Dahlhaus, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194574 · Cited by 24
SOUSA, R. T. D., Busnello, J. V., Forlenza, O. V., Zanetti, M. V., Soeiro‐de‐Souza, M. G., van de Bilt, M. T., Moreno, R. A., Zarate, C. A., Gattaz, W. F., & Machado‐Vieira, R. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.011 · Cited by 17
“, 2008), antidepressants in unipolar depression (Szegedi et al., 2009), and mood stabilizers and atypical antipsychotics in bipolar depression (Kemp et al.”
BackgroundResultBae, K., Kim, S., Kim, J. M., Shin, I., Yoon, J., Jung, S.-W., Lee, M., Yim, H. W., & Jun, T. (2011) · Psychiatry Investigation · doi:10.4306/pi.2011.8.3.234 · Cited by 23
The effectiveness of initial therapy contact: A systematic review
Doorn, K. A., & Sweeney, K. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2019.101786 · Cited by 24
Wu, P., Zhang, A., Sun, N., Lei, L., Liu, P., Wang, Y., Li, H., Yang, C., & Zhang, K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.751756 · Cited by 18
Bareš, M., Novák, T., Kopeček, M., Stopková, P., Kožený, J., & Höschl, C. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.05.002 · Cited by 17
“Based on our data (no detected differences among AUCs of various threshold of MADRS reduction at both times) using the 20% reduction of MADRS score might be clinically useful for prediction since this metric achieved numerically highest values of AUCs at both time periods and its predictive effect was demonstrated in…”
BackgroundMethodResultInfluentialFurukawa, T. A., Kato, T., Shinagawa, Y., Miki, K., Fujita, H., Tsujino, N., Kondo, M., Inagaki, M., & Yamada, M. (2018) · Psychological Medicine · doi:10.1017/s0033291718003331 · Cited by 17
“Observations early in the course of the treatment can also be informative: early improvement within 1–3 weeks of treatment has been found repeatedly to be a predictor of good outcomes (Katz et al., 2004; Henkel et al., 2009; Szegedi et al., 2009; Tadic et al., 2010).”
Early score fluctuation and placebo response in a study of major depressive disorder
Targum, S. D., Cameron, B. R., Ferreira, L., & MacDonald, I. D. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.11.014 · Cited by 18
Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants
Kang, H., Kim, K., Yoo, K.-H., Park, Y., Kim, J., Kim, J., Shin, I.-S., Kim, J. H., & Kim, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144884 · Cited by 16
“Based on the predictive role of early improvement in later remission [16,17], better treatment outcomes were observed when treatment strategies were changed according to early improvement status [57].”
BackgroundXu, Z., Chen, Z., Shen, T., Chen, L., Tan, T., Gao, C., Chen, B., Yuan, Y., & Zhang, Z. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13314 · Cited by 23
“Keywords: HTR1A, HTR1B, methylation, polymorphism. http://onlinelibrary.wiley.com/doi/10.1111/pcn.13314/full Major depressive disorder (MDD) is a common psychiatric disorder affecting more than 240 million people worldwide.1 MDD is one of the leading causes of disability around the world and contributes greatly to the…”
BackgroundInfluentialChae, W. R., Nagel, J. M., Kuehl, L. K., Gold, S. M., Wingenfeld, K., & Otte, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.044 · Cited by 18
Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie
Unterecker, S., Hefner, G., Baumann, P., Gründer, G., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., et al. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0643-9 · Cited by 16
Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression
Li, X., Pei, C., Wang, X., Wang, H., Tian, S., Yao, Z., & Lü, Q. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27577 · Cited by 16
“In addition, the occurrence of improvement signifies a greater chance of a stable response and remission.(9) It is possible that imaging biomarkers could be identified by constructing a baseline model which would guide the choice of the optimal antidepressant drug that would lead to early improvement.”
BackgroundZou, S., Dai, L., Wang, P., Du, H., Guo, Q., Li, F., & He, X. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666211104123343 · Cited by 16
Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
Psomiades, M., Mondino, M., Galvão, F., Mandairon, N., Nourredine, M., Suaud‐Chagny, M., & Brunelin, J. (2022) · Brain Sciences · doi:10.3390/brainsci12020126 · Cited by 17
“Interestingly, retrospective studies showed that, after 2 weeks of treatment, the early non-improvement of depressive symptoms was a specific marker of final treatment failure [23] and that early changes in BDNF levels may predict the pharmacological treatment outcome [24,25].”
BackgroundRoxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
Li, A., Liu, Z., Ali, T., Gao, R., Luo, Y., Gong, Q., Zheng, C., Li, W., Guo, H., Liu, X., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1048985 · Cited by 16
“However, conventional antidepressants show their effects slowly and may take about 2–3 weeks (Szegedi et al., 2009), immediate/quick antidepressant effects of several compounds/drugs (including Roxadustat treated here for 3 days) have also been documented in the LPS-induced model of depression (O’Connor et al.”
BackgroundClinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
Christensen, M. C., McIntyre, R. S., Adair, M., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002249 · Cited by 15
Yang, S.-J., Stewart, R. J., Kang, H., Kim, S., Bae, K., Kim, J., Jung, S.-W., Lee, M., Yim, H. W., & Jun, T. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.004 · Cited by 16
Funaki, K., Nakajima, S., Suzuki, T., Mimura, M., & Uchida, H. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.710 · Cited by 16
Tokuoka, H., Takahashi, H., Ozeki, A., Kuga, A., Yoshikawa, A., Tsuji, T., & Wohlreich, M. M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.039 · Cited by 17
McIntyre, R. S., Gorwood, P. A. P. M., Thase, M. E., Liss, C., Desai, D., Chen, J., & Bauer, M. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000416 · Cited by 19
Self-citationGraham, B., Garcia, N. M., Burton, M. S., Cooper, A. A., Roy‐Byrne, P., MAVISSAKALIAN, M. R., Feeny, N. C., & Zoellner, L. A. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.211 · Cited by 16
“Consensus is lacking regarding whether early response to pharmaco-therapy for depression and anxiety disorders reflects true psycho-tropic 4,29 or placebo effects 30 and regarding specific mechanisms through which placebo effects occur.”
Birkenhäger, T. K., Roos, J., & Kamperman, A. M. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13054 · Cited by 16
“21 Previous ECT treatment 6 (25) 13 (20) 19 (21) Χ(2) = 0.”
Does early improvement in major depression protect against treatment emergent suicidal ideation?
Seemüller, F., Schennach-Wolff, R., Obermeier, M., Henkel, V., Möller, H. J., & Riedel, M. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.010 · Cited by 15
“More recently, this view has been questioned by a large number of authors, who not only emphasized that an earlier onset before two weeks was highly prevalent but also showed that it was highly predictive of later outcome (Henkel et al., 2009; Nierenberg et al., 1995; Szegedi et al., 2009; Tadic et al., 2009; van Calk…”
BackgroundSzegedi, A., Zhao, J., & McIntyre, R. S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.024 · Cited by 14
Self-citationThe keys to improving depression outcomes
Rizvi, S. J., & Kennedy, S. H. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.002 · Cited by 16
“There has been considerable evidence demonstrating that monoamine antidepressants have a delayed onset of action of approximately 2 weeks or more; however, more recent data suggests antidepressants have effects as early as one week (Anderson et al., 2008; Szegedi et al., 2009).”
BackgroundDai, Z., Pei, C., Zhang, S., Tian, S., Chen, Z., Zhou, H., Lü, Q., & Yao, Z. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13787 · Cited by 14
Petersen, J. J., Hartig, J., Paulitsch, M., Pagitz, M., Mergenthal, K., Rauck, S., Reif, A., Gerlach, F. M., & Gensichen, J. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202245 · Cited by 14
Andresen, E. L., Wilson, K., Castillo, A., & Koopman, C. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328332055c · Cited by 18
“It is now accepted that if a patient shows early improvement to a drug in a clinical trial, that patient will likely stabilize while on that specific drug (Szegedi et al., 2009).”
BackgroundLoebel, A. D., Citrome, L., Correll, C. U., Xu, J., Cucchiaro, J. B., & Kane, J. M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0629-0 · Cited by 14
“This finding has been reported not only for schizophrenia [1], but also in the treatment of major depressive disorder [17, 18] and acute bipolar mania [19].”
BackgroundShi, L., Wang, J., Xu, S., & Lu, Y. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s122085 · Cited by 13
“Early improvement in the course of treatment is regarded as predictive of later remission and better functional recovery; this has been confirmed by previous studies on SSRIs, serotonin–norepinephrine reuptake inhibitors, TCAs, and others.(19,21) All of these results suggested that vilazodone might at least be an effe…”
ResultSackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Self-citationChen, T., & Tzeng, N. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.05.009 · Cited by 15
“Early improvement with antidepressant medication predicts a positive treatment outcome with high sensitivity in patients with MDD [8] so that a poor treatment response during the first two weeks may indicate that changes in depression management should be considered [9].”
BackgroundLin, C., Chen, C., Wang, F., & Lane, H. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12046 · Cited by 13
Bitran, S., Farabaugh, A. H., Ameral, V., LaRocca, R. A., Clain, A. J., D, M. F. M., & Mischoulon, D. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328343ba08 · Cited by 13
“…behavioral therapy (Coryell et al., 1982; Quitkin et al., 1984; Downing and Rickels, 1985; Stassen et al., 1993; Nierenberg et al., 1995, 2000; Bech, 2001; Kieser and Szegedi, 2005; Szegedi et al., 2003, 2009; Henkel et al., 2009; Wade et al., 2009; Nakajima et al., 2010; Tadić et al., 2010).”
BackgroundHelmreich, I., Wagner, S., König, J., Kohnen, R., Szegedi, A., Hiemke, C., & Tadić, A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.043 · Cited by 18
“Many retrospective studies with virtually all groups of antidepressants (Bares et al., 2012; Gorwood et al., 2013; Henkel et al., 2009; Kim et al., 2011; Lam, 2012; Ostad Haji et al., 2013; Papakostas et al., 2006; Posternak and Zimmerman, 2005; Stassen et al., 2007; Szegedi et al., 2009; Tadić et al., 2010; Taylor et…”
BackgroundSelf-citationManagement of Chronic Depressive Patients with Residual Symptoms
Han, C., Yeh, T. L., Kato, M., Sato, S., Chang, C., & Pae, C.-U. (2013) · CNS Drugs · doi:10.1007/s40263-012-0034-x · Cited by 13
“Aripiprazole augmentation might be initiated much earlier than the time that this case was given it because patients with early response in an earlier treatment phase may have a better treatment outcome than those without early response in an earlier treatment phase [3, 19–21].”
BackgroundHou, Z., Kong, Y., Yin, Y., Zhang, Y., & Yuan, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110038 · Cited by 13
Singh, M. K., & Thase, M. E. (2025) · CNS Spectrums · doi:10.1017/s1092852925000094 · Cited by 18
“67,68 71 SPCD is a two-stage study design in which a much higher proportion of patients are randomized to receive a double-blind placebo in the first stage.”
Self-citationReplication of distinct trajectories of antidepressant response to intravenous ketamine
O’Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Swann, A. C., Murphy, N., Tamman, A. J. F., Amarneh, D. Y., Lijffijt, M., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.031 · Cited by 16
Belanger, H. G., Lee, C. M., Poliacoff, Z., Gupta, C., & Winsberg, M. E. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001638 · Cited by 17
“Some have determined that lack of at least 20% improvement by 2 weeks is sufficient reason to switch.(10) However, efforts to calculate the positive predictive value (PPV) and negative predictive value (NPV) of at least 20% improvement by 2 weeks for response and remission over 12 weeks have indicated that predictive…”
BackgroundKhoo, Y., Demchenko, I., Frey, B. N., Milev, R. V., Ravindran, A. V., Parikh, S. V., Ho, K. T., Rotzinger, S., Lou, W. Y. W., Lam, R. W. M., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.027 · Cited by 15
Hashikawa, N., Ogawa, T., Sakamoto, Y., Ogawa, M., Matsuo, Y., Zamami, Y., & Hashikawa‐Hobara, N. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0174-x · Cited by 12
“If patients are showing improvement of symptoms following 2 weeks of antidepressant treatment, they are considered responders (Szegedi et al. 2009; Van Calker et al. 2009).”
BackgroundInfluentialAngstman, K. B., Rohrer, J. E., & Rasmussen, N. H. (2011) · Journal of Primary Care & Community Health · doi:10.1177/2150131911423824 · Cited by 11
Implementing Treatment Strategies for Different Types of Depression
McIntyre, R. S. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14077su1c.02 · Cited by 15
Hicks, P. B., Sevilimedu, V., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., Vertrees, J. E., Mohamed, S., & Zisook, S. (2019) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20190003 · Cited by 12
Boessen, R., Knol, M. J., Groenwold, R. H. H., Grobbee, D. E., & Roes, K. C. B. (2012) · Clinical Trials · doi:10.1177/1740774512456454 · Cited by 12
An, J., Li, L., Wang, L., Su, Y., Wang, Y., Li, K., Zeng, Y., Kong, Q., Yan, C., & Si, T. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00884 · Cited by 13
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
“The duration of this latency of effect has been assessed and defined differently over the decades: while originally a latency of up to six weeks was assumed, later meta-analyses suggested a latency of about two weeks until the onset of antidepressant effects (see e.g. [32, 33]).”
Furukawa, T. A., Noma, H., Tajika, A., Toyomoto, R., Sakata, M., Luo, Y., Horikoshi, M., Akechi, T., Kawakami, N., Nakayama, T., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01906-6 · Cited by 11
Wagner, S., Tadić, A., Roll, S. C., Engel, A., Dreimüller, N., Engelmann, J., & Lieb, K. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.042 · Cited by 12
Factors associated with early and late response to electroconvulsive therapy
Hart, K. L., McCoy, T. H., Henry, M., Seiner, S. J., & Luccarelli, J. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13537 · Cited by 12
Katzman, M. A., Nierenberg, A. A., Wajsbrot, D., Meier, E., Prieto, R., Pappadopulos, E. A., Mackell, J. A., & Boucher, M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000775 · Cited by 11
“In a meta-analysis of 41 antidepressant trials, the positive predictive value of early improvement was similar for predicting remission in placebo and active treatment groups, but for predicting response, positive predictive value seemed to be lower for the placebo group.(9) In the current analysis, greater numbers of…”
MethodResultRicken, R., Wiethoff, K., Reinhold, T., Stamm, T. J., Baghai, T. C., Fisher, R. B., Seemüller, F., Brieger, P., Cordes, J., Laux, G., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.051 · Cited by 11
Metadata
- Authors
- Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E.
- Affiliations
- University of Pennsylvania (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-02-24
- Volume
- 70
- Issue
- 3
- Pages
- 344-353
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2132699864
- Cited by
- 341
- References
- 0
- Citations by year
- 2026: 22 · 2025: 11 · 2024: 17 · 2023: 25 · 2022: 23 · 2021: 18 · 2020: 13 · 2019: 23 · 2018: 14 · 2017: 20 · 2016: 20 · 2015: 23 · 2014: 14 · 2013: 25 · 2012: 24
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, mirtazapine, early treatment response, treatment outcome prediction, antidepressant response, remission, rapid titration, dose titration, Hamilton Depression Rating Scale, predictive validity, negative predictive value, positive predictive value, sensitivity and specificity, antidepressant trials, inpatients and outpatients, treatment-resistant depression
- MeSH terms
- Mirtazapine, Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Humans, Mianserin, Personality Inventory, Prognosis, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.